All updated as on -
Forecasts indicate that the needle-free injection system market will reach a value of $422.40 million by 2031, expanding at a CAGR of 15.15% from 2024 to 2031.
To avoid puncturing the skin with a traditional needle, needle-free injection methods are utilized to inject patients with liquid formulations, medications, and vaccines. Because these systems enhance the immune response to vaccines, remove needle dangers, and lower healthcare costs, their demand has grown significantly in recent years. Nevertheless, the business is hindered by a shortage of trained experts and the limited adoption of intravenous injection systems that do not require needles.
One alternative to needles is a system that uses pressure, electrophoresis force, shock waves, or Lorentz force to inject medicine under the skin. Many people believe that needle-free injection devices are better than hypodermic needles since they can be used multiple times without spreading illnesses. Injectable medication delivery systems like this make needlestick injuries and agony a thing of the past. A number of factors are propelling the market forward, including the growing number of people living with diabetes, the need for self-injection devices, and the prevalence of infectious diseases caused by needlestick injuries. Potential challenges to the expansion of the needle-free injection system industry include a greater development cost compared to traditional injection systems, a general lack of knowledge about these systems, and restrictions on their use in intravenous drug administration.
The best-case scenario would have the needle-free injection system market benefiting from the COVID-19 epidemic. Since the start of the COVID-19 pandemic in December 2019, the market for needle-free injection systems has been booming due to the high demand for self-injectable devices and mass vaccinations. Many companies in the needle-free injection system business have teamed up with other companies and government organizations to conduct research and development on a needle-free injection system to combat the rising number of instances in different locations.
The ideal method of drug administration would be to avoid needles as much as possible for the sake of convenience and painlessness. A variety of medical issues can be treated with needle-free injection methods. The predicted growth in the prevalence of chronic disorders, such as diabetes and osteoporosis, is expected to drive the needle free injection system market value higher throughout the projected time.
Markets for medical devices and advanced products are expected to have significant expansion in the near future, driven by rising investment in R&D in both developed and emerging nations. The market is anticipated to be driven by the research and development capabilities that are being utilized to create medical devices. Equipment that can intelligently capture and evaluate test data in compliance with government requirements while efficiently performing all product testing is essential when creating drug-delivery device systems. In order for manufacturers to be able to update and expand the test system as needed, it needs to be both flexible and modular.
The significant investment required to create needle-free injection methods can delay the expansion of the market. Higher labor and infrastructural expenditures, along with a high cost per unit of output, are the sources of these costs. Additionally, the high cost of technologies leads to high development expenses. The most cost-effective choices also include standard and sterile needles. When compared to traditional needle injections, the prohibitive cost of needle-free injection devices (ranging from $5 to $15 for 1,000 doses) becomes a major concern. Consequently, the development cost may hinder market expansion when compared to the standard injection system approach.
Anemia, cancer, diabetes, hepatitis, and a host of other acute and chronic illnesses are finding new life with biosimilars. The need for biosimilars is growing in tandem with the incidence of these diseases. As a result, there is a great chance for pharmaceutical and medical device companies to come up with new ways to provide biosimilars. The needle-free technology offers a safe and user-friendly alternative to standard injection methods for providing biosimilars, which is especially useful as many vaccinations and biosimilars are provided by injections.
In addition, numerous companies in the biopharmaceutical, vaccine, and needle-free device industries are concentrating on launching safe and effective drug delivery devices that use needle-free injection technology, as well as on strategic acquisitions and partnerships to take advantage of the vaccines market's potential for growth. For example, the first needle-free injection of a plasmid DNA COVID-19 vaccination was announced for sale in August 2021 by PharmaJet and Zydus Cadila after receiving EUA approval. In addition, a collaboration between PharmaJet and Abnova to create and distribute a needle-free injection vaccination against COVID-19 has been launched. In addition, the Implavax needle-free injection device was developed in collaboration between Enesi Pharma and Geovax in January 2019.
Report Coverage
Global Needle Free Injection System research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Needle Free Injection System report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Needle Free Injection System competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Needle Free Injection System market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Needle Free Injection System market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Needle Free Injection System market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
CROSSJECT NEEDLE FREE INJECTION SYSTEMS, VALERITAS HOLDINGS, INC., PHARMAJET, NATIONAL MEDICAL PRODUCTS, INC., MEDICAL INTERNATIONAL TECHNOLOGY, INC., ANTARES PHARMA, INC., THE EUROPEAN PHARMA GROUP, INJEX PHARMA AG
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Needle Free Injection System market based on the below-mentioned segments:
Global Needle Free Injection System Market, By Type
Liquid-based
Projectile/Depot-based
Powder-based
Global Needle Free Injection System market, By Application
Vaccine Delivery
Insulin Delivery
Pain Management
Others
Global Needle Free Injection System Market, By End User
Hospitals & Clinics
Home Care Settings
Research Laboratories
Others
Global Needle Free Injection System market, Regional Analysis
To avoid puncturing the skin with a traditional needle, needle-free injection methods are utilized to inject patients with liquid formulations, medications, and vaccines. Because these systems enhance the immune response to vaccines, remove needle dangers, and lower healthcare costs, their demand has grown significantly in recent years. Nevertheless, the business is hindered by a shortage of trained experts and the limited adoption of intravenous injection systems that do not require needles.
One alternative to needles is a system that uses pressure, electrophoresis force, shock waves, or Lorentz force to inject medicine under the skin. Many people believe that needle-free injection devices are better than hypodermic needles since they can be used multiple times without spreading illnesses. Injectable medication delivery systems like this make needlestick injuries and agony a thing of the past. A number of factors are propelling the market forward, including the growing number of people living with diabetes, the need for self-injection devices, and the prevalence of infectious diseases caused by needlestick injuries. Potential challenges to the expansion of the needle-free injection system industry include a greater development cost compared to traditional injection systems, a general lack of knowledge about these systems, and restrictions on their use in intravenous drug administration.
The best-case scenario would have the needle-free injection system market benefiting from the COVID-19 epidemic. Since the start of the COVID-19 pandemic in December 2019, the market for needle-free injection systems has been booming due to the high demand for self-injectable devices and mass vaccinations. Many companies in the needle-free injection system business have teamed up with other companies and government organizations to conduct research and development on a needle-free injection system to combat the rising number of instances in different locations.
The ideal method of drug administration would be to avoid needles as much as possible for the sake of convenience and painlessness. A variety of medical issues can be treated with needle-free injection methods. The predicted growth in the prevalence of chronic disorders, such as diabetes and osteoporosis, is expected to drive the needle free injection system market value higher throughout the projected time.
Markets for medical devices and advanced products are expected to have significant expansion in the near future, driven by rising investment in R&D in both developed and emerging nations. The market is anticipated to be driven by the research and development capabilities that are being utilized to create medical devices. Equipment that can intelligently capture and evaluate test data in compliance with government requirements while efficiently performing all product testing is essential when creating drug-delivery device systems. In order for manufacturers to be able to update and expand the test system as needed, it needs to be both flexible and modular.
The significant investment required to create needle-free injection methods can delay the expansion of the market. Higher labor and infrastructural expenditures, along with a high cost per unit of output, are the sources of these costs. Additionally, the high cost of technologies leads to high development expenses. The most cost-effective choices also include standard and sterile needles. When compared to traditional needle injections, the prohibitive cost of needle-free injection devices (ranging from $5 to $15 for 1,000 doses) becomes a major concern. Consequently, the development cost may hinder market expansion when compared to the standard injection system approach.
Anemia, cancer, diabetes, hepatitis, and a host of other acute and chronic illnesses are finding new life with biosimilars. The need for biosimilars is growing in tandem with the incidence of these diseases. As a result, there is a great chance for pharmaceutical and medical device companies to come up with new ways to provide biosimilars. The needle-free technology offers a safe and user-friendly alternative to standard injection methods for providing biosimilars, which is especially useful as many vaccinations and biosimilars are provided by injections.
In addition, numerous companies in the biopharmaceutical, vaccine, and needle-free device industries are concentrating on launching safe and effective drug delivery devices that use needle-free injection technology, as well as on strategic acquisitions and partnerships to take advantage of the vaccines market's potential for growth. For example, the first needle-free injection of a plasmid DNA COVID-19 vaccination was announced for sale in August 2021 by PharmaJet and Zydus Cadila after receiving EUA approval. In addition, a collaboration between PharmaJet and Abnova to create and distribute a needle-free injection vaccination against COVID-19 has been launched. In addition, the Implavax needle-free injection device was developed in collaboration between Enesi Pharma and Geovax in January 2019.
Report Coverage
Global Needle Free Injection System research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Needle Free Injection System report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Needle Free Injection System competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Needle Free Injection System market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2031 |
| Base Year | 2024 |
| Forecast Period | 2024-2031 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | CROSSJECT NEEDLE FREE INJECTION SYSTEMS, VALERITAS HOLDINGS, INC., PHARMAJET, NATIONAL MEDICAL PRODUCTS, INC., MEDICAL INTERNATIONAL TECHNOLOGY, INC., ANTARES PHARMA, INC., THE EUROPEAN PHARMA GROUP, INJEX PHARMA AG |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Needle Free Injection System Market from 2021 to 2031.
- Market Forecast for Needle Free Injection System Market from 2021 to 2031.
- Regional Market Share and Revenue from 2021 to 2031.
- Country Market share within region from 2021 to 2031.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Needle Free Injection System competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Needle Free Injection System
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Needle Free Injection System market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Needle Free Injection System market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
CROSSJECT NEEDLE FREE INJECTION SYSTEMS, VALERITAS HOLDINGS, INC., PHARMAJET, NATIONAL MEDICAL PRODUCTS, INC., MEDICAL INTERNATIONAL TECHNOLOGY, INC., ANTARES PHARMA, INC., THE EUROPEAN PHARMA GROUP, INJEX PHARMA AG
Primary Target Market
- Market Players of Needle Free Injection System
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Needle Free Injection System market based on the below-mentioned segments:
Global Needle Free Injection System Market, By Type
Liquid-based
Projectile/Depot-based
Powder-based
Global Needle Free Injection System market, By Application
Vaccine Delivery
Insulin Delivery
Pain Management
Others
Global Needle Free Injection System Market, By End User
Hospitals & Clinics
Home Care Settings
Research Laboratories
Others
Global Needle Free Injection System market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive needle free injection system market market research and competitor analysis for your business to help you develop more profound insights into the needle free injection system market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the needle free injection system market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.